摘要
目的 研究用流式细胞术免疫表型分析t(8;2 1) (q2 2 ;q2 2 )急性髓系白血病 (AML)的免疫表型特点。方法 采用常规细胞形态学 /细胞化学、流式细胞术间接免疫荧光标记技术和R显带核型分析 (MIC)进行分型 ,部分加用RT PCR检测AML1/ETO融合基因。结果 ① 2 94例初治AML患者中 ,6 4例t(8;2 1)AML ,占 2 1.8% ,在M2 中高达 5 4.7%。 6 4例t(8;2 1)AML中M2 占 81.3% ;②与对照组比较 ,t(8;2 1)AML高表达CD19和CD3 4,低表达CD3 3 (P <0 .0 0 1) ;③以 2 0 %阳性细胞作为阳性标准 ,CD19阳性率在AML为 13.6 % (2 94例中 40例 ) ,t(8;2 1)AML为 5 0 % (6 4例中 32例 ) ,显著高于无t(8;2 1)AML组的 3 5 % (2 30例中 8例 ) (P <0 .0 0 1) ;④在t(8;2 1)AML患者中 ,CD19+ 和 (或 )CD3 4+ 5 8例 (90 .6 % )、CD19-和 (或 )CD3 4-6例 (9.4% )。结论 t(8;2 1)AML特别是M2 /t(8;2 1)高表达CD19与CD3 4,CD19与t(8;2 1)密切相关 ,CD19是预测t(8;2 1)
Objective To study the predictive value of immunophenotypical features in t(8;21)(q22;q22)acute myeloid leukemia(AML). Methods Morphological/cytochemical,flow cytometric immunophenotyping,cytogenetic analyses(MIC) and RT PCR were performed in 294 previously untreated AML. Results ①In 294 AML patients, t(8;21)AML were 21.8%(64); in AML M 2,t(8;21) AML were 54.7%; and in t(8;21)AML, AML M 2 were 81.3%. ②Compared with control group, CD 19 and CD 34 expressions were higher, and CD 33 expression was lower(P<0.001) in t(8;21)AML. ③If the cut off value of CD 19 positive was ≥20%, CD 19 positive rate was 13 6%(40/294) in AML,and 50%(32/64) and 3.5%(8/230)(P<0.001) in t(8;21)AML and control group. ④CD 19 + and/or CD 34 + t(8;21)AML accounted for 90.6%(58/64) of t(8;21) AML and CD 19 -/CD 34 - for 9.6% (6/64). Conclusion In t(8;21)AML,especially M 2/t(8;21), CD 19 and CD 34 expressions were high. CD 19 was one of predictive markers of t(8;21) AML.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2001年第6期313-315,共3页
Chinese Journal of Hematology
关键词
急性髓系白血病
免疫表型
流式细胞术
单克隆抗体
Leukemia,myeloid,acute
Flow cytometry
Immunophenotypical analysis
Monoclonal antibody,CD 19
Diagnosis
